Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

02 May 2003

Inhibition of the activity of poly(ADP-ribose) polymerase in haemorrhagic shock

M. McDonald, H. Mota-Filipe, M. Abdelrahman, M. Threadgill, C. Thiemermann

Med Sci Monit 2003; 9(1): 41- :: ID: 15104

Abstract

There is good evidence that haemorrhagic shock is associated with the generation of reactive oxygen species (ROS) including superoxide anions and hydrogen peroxide [1]. It has been suggested that the activation of PARP plays a role in the cardiovascular failure associated with haemorrhagic shock [2], but there is little information regarding the role of PARP in the pathophysiology of the organ dysfunction/injury associated with haemorrhagic shock. Here we investigate the effects of several PARP inhibitors on the circulatory failure and the organ injury and dysfunction caused by severe haemorrhage and resuscitation in the anaesthetised rat. Male Wistar rats were anaesthetised with thiopentone sodium (120 mg/kg i.p.) and instrumented for the measurement of mean arterial pressure and heart rate. Haemorrhage (to lower blood pressure to ~50 mmHg for 90 min) and resuscitation (with blood and an equivalent volume of Ringers Lactate solution), resulted within 4 h in a delayed fall in blood pressure as well as in renal dysfunction, liver injury and dysfunction, pancreatic injury, and neuromuscular injury. Treatment of rats subjected to haemorrhage and resuscitation with the PARP inhibitors 3-aminobenzamide (10 mg/kg), nicotinamide (10 mg/kg), or 1,5 dihydroxyisoquinoline (ISO, 3 mg/kg) attenuated the multiple organ injury and dysfunction caused by haemorrhage and resuscitation. However, treatment with the vehicle for ISO (10% v/v DMSO) had a similar effect. As the beneficial effects of ISO (the most potent and specific PARP inhibitor) were, in part, due to its vehicle, further studies with the potent, specific and water soluble inhibitor of PARP activity, 5-aminoisoquinolinone (5-AIQ), were performed to ensure that the reduction by the agents of the multiple organ failure in haemorrhagic shock is indeed due to their ability to inhibit PARP activity. Administration (5 min prior to resuscitation of 5-AIQ (0.03 mg/kg i.v, or 0.3 mg/kg i.v.) reduced (in a dose-related fashion) the multiple organ injury and dysfunction, but did not affect the circulatory failure, associated with haemorrhagic shock. In conclusion, this study demonstrates that chemically distinct inhibitors of PARP activity attenuate the renal dysfunction, the hepatocellular injury and the pancreatic injury associated with severe haemorrhage and resuscitation. References: 1.Redl H, Gasser H, Schlag G, Marzi I: Involvement of oxygen radicals in shock related cell injury. Br Med Bull, 1993; 49: 556-65 2.Szabo C: Potential role of peroxynitrite-poly (ADP-ribose) synthetase pathway in a rat model of severe hemorrhagic shock. Shock, 1998; 9: 341-344

Keywords: PARP, haemorrhage, multiple organ injury, Shock

0 Comments

Editorial

01 December 2022 : Editorial  

Editorial: The World Health Organization (WHO) Fungal Priority Pathogens List in Response to Emerging Fungal Pathogens During the COVID-19 Pandemic

Dinah V. Parums
Science Editor, Medical Science Monitor, International Scientific Information, Inc., Melville, NY, USA

DOI: 10.12659/MSM.939088

Med Sci Monit 2022; 28:e939088

SARS-CoV-2/COVID-19

29 November 2022 : Clinical Research  

Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...

Med Sci Monit In Press; DOI: 10.12659/MSM.938647  

24 November 2022 : Clinical Research  

A Prospective Questionnaire-Based Study to Evaluate Factors Affecting the Decision to Receive COVID-19 Vacc...

Med Sci Monit In Press; DOI: 10.12659/MSM.938665  

01 November 2022 : Clinical Research  

Questionnaire-Based Study of 81 Patients in Poland to Evaluate the Course of Inflammatory Bowel Disease and...

Med Sci Monit 2022; 28:e938243

In Press

02 Dec 2022 : Clinical Research  

Value of Early Laparoscopic Exploration for Primary Infertile Patients with Patent Fallopian Tubes Complica...

Med Sci Monit In Press; DOI: 10.12659/MSM.938637  

30 Nov 2022 : Clinical Research  

Retrospective Evaluation of Hematological and Clinical Factors Associated with 30-Day Mortality in 170 Pati...

Med Sci Monit In Press; DOI: 10.12659/MSM.938674  

29 Nov 2022 : Clinical Research  

Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...

Med Sci Monit In Press; DOI: 10.12659/MSM.938647  

28 Nov 2022 : Review article  

A Review of the Roles of Apelin and ELABELA Peptide Ligands in Cardiovascular Disease, Including Heart Fail...

Med Sci Monit In Press; DOI: 10.12659/MSM.938112  

Most Viewed Current Articles

13 Nov 2021 : Clinical Research  

Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...

DOI :10.12659/MSM.932788

Med Sci Monit 2021; 27:e932788

30 Dec 2021 : Clinical Research  

Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...

DOI :10.12659/MSM.935379

Med Sci Monit 2021; 27:e935379

01 Nov 2020 : Review article  

Long-Term Respiratory and Neurological Sequelae of COVID-19

DOI :10.12659/MSM.928996

Med Sci Monit 2020; 26:e928996

08 Mar 2022 : Review article  

A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...

DOI :10.12659/MSM.936292

Med Sci Monit 2022; 28:e936292

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750